Skip to contentA
Aclaris Therapeutics, Inc.
A
ACRSAclaris Therapeutics, Inc. Q1 2019 · 10-Q
Revenue$1.26M$1.26M+13.0% vs Q1 2018 Net Income-$37.57M-$37.57MN/M vs Q1 2018 EPS Diluted-$0.91-$0.91N/M vs Q1 2018 Operating Income-$27,051,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aclaris Therapeutics, Inc. · CIK 1557746 · Engraved from SEC EDGAR
Free Cash Flowderived-$31,602,000N/M Margins · derivedOperating margin-2141.8%+626.4 pt vs Q1 2018
Net margin-2974.3%−270.4 pt vs Q1 2018
ended Mar 31, 2019 · filed May 8, 2019 · 38 d after period end